[go: up one dir, main page]

PE20040623A1 - COMBINATION OF NMDA ANTAGONIST WITH ACETYLCHOLINE ESTERASE INHIBITORS - Google Patents

COMBINATION OF NMDA ANTAGONIST WITH ACETYLCHOLINE ESTERASE INHIBITORS

Info

Publication number
PE20040623A1
PE20040623A1 PE2003000527A PE2003000527A PE20040623A1 PE 20040623 A1 PE20040623 A1 PE 20040623A1 PE 2003000527 A PE2003000527 A PE 2003000527A PE 2003000527 A PE2003000527 A PE 2003000527A PE 20040623 A1 PE20040623 A1 PE 20040623A1
Authority
PE
Peru
Prior art keywords
combination
acetylcholine esterase
nmda antagonist
esterase inhibitors
inhibitors
Prior art date
Application number
PE2003000527A
Other languages
Spanish (es)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PE20040623A1 publication Critical patent/PE20040623A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (A) UNO O MAS INHIBIDORES DE ACELTILCOLINESTERASA O UNA SAL DEL MISMO TAL COMO TACRINA, DONEPEZIL, RIVASTIGMINA, ENTRE OTROS; (B) UNO O MAS ANTAGONISTAS DE NMDA COMO MEMANTINA. DONDE (A) Y (B) PUEDEN HALLARSE EN EL MISMO VEHICULO O NO; Y PUEDEN SER ADMINISTRADOS SIMULTANEAMENTE O CONCOMITANTEMENTE. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL ALZHEIMER, DEL DETERIORO COGNITIVO LEVE O LA DEMENCIAIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: (A) ONE OR MORE ACELTILCOLINESTERASE INHIBITORS OR A SALT OF THE SAME SUCH AS TACRINE, DONEPEZIL, RIVASTIGMINE, AMONG OTHERS; (B) ONE OR MORE NMDA ANTAGONISTS AS MEMANTINE. WHERE (A) AND (B) CAN BE FOUND IN THE SAME VEHICLE OR NOT; AND THEY CAN BE ADMINISTERED SIMULTANEOUSLY OR CONCOMITANTLY. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF ALZHEIMER, MILD COGNITIVE IMPAIRMENT OR DEMENTIA

PE2003000527A 2002-05-31 2003-05-29 COMBINATION OF NMDA ANTAGONIST WITH ACETYLCHOLINE ESTERASE INHIBITORS PE20040623A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200844 2002-05-31

Publications (1)

Publication Number Publication Date
PE20040623A1 true PE20040623A1 (en) 2004-09-11

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000527A PE20040623A1 (en) 2002-05-31 2003-05-29 COMBINATION OF NMDA ANTAGONIST WITH ACETYLCHOLINE ESTERASE INHIBITORS

Country Status (9)

Country Link
KR (1) KR101016927B1 (en)
CN (1) CN1655793A (en)
AR (1) AR040121A1 (en)
CA (1) CA2426492C (en)
EA (1) EA007632B1 (en)
IS (1) IS7558A (en)
PE (1) PE20040623A1 (en)
UA (1) UA82480C2 (en)
ZA (1) ZA200409147B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107653U (en) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" COMPOSITION OF MEDICINAL PRODUCTS FOR TREATMENT AND PREVENTION OF BEHAVIORAL, MENTAL, AND COGNITIVE DISORDERS
CN118239847A (en) * 2014-05-29 2024-06-25 广州喜鹊医药有限公司 Preparation method of amantadine nitrate compound with neuroprotection effect
WO2018062941A1 (en) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 Pharmaceutical composition for preventing or treating dementia and cognitive dysfunction, containing donepezil or pharmaceutically acceptable salt thereof and memantine or pharmaceutically acceptable salt thereof, and preparation method therefor
KR20210072569A (en) 2019-12-09 2021-06-17 주식회사 종근당 Complex formulation comprising donepezil and memantine

Also Published As

Publication number Publication date
EA007632B1 (en) 2006-12-29
EA200401617A1 (en) 2005-06-30
AR040121A1 (en) 2005-03-16
KR20050024296A (en) 2005-03-10
IS7558A (en) 2004-11-26
CA2426492A1 (en) 2003-09-16
CA2426492C (en) 2006-10-03
ZA200409147B (en) 2006-06-28
KR101016927B1 (en) 2011-02-28
UA82480C2 (en) 2008-04-25
CN1655793A (en) 2005-08-17

Similar Documents

Publication Publication Date Title
TR200102647T2 (en) Compositions for improving fertility
CL2010001160A1 (en) Compounds derived from 3,8-diazabicyclo [4.2.0] octane and 3,6-diazabicyclo [3.2.0] heptane; pharmaceutical composition; orexin reeptor modulators, useful in the treatment of insomnia.
UY26482A1 (en) BIPHENYL SULPHONAMIDES AS ANGIOTENSIN RECEPTOR ANTAGONISTS
PA8587101A1 (en) NEW DERIVATIVES OF DIHYDROPIRIMIDO [4,5-D] PIRIMIDINONE REPLACED BY AMIINO, MANUFACTURE AND USE OF THE SAME AS PHARMACEUTICAL AGENTS
CO4560552A1 (en) NON-PEPTIDIC TACHYCIN RECIPIENT ANTAGONISTS
ATE296094T1 (en) NITROGEN MONOXIDE FORMING COMPOSITIONS FOR THE TREATMENT OF NAILBED INFECTIONS
DE69727158D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A MIXTURE OF SELF-CROSS-LINKED AND NON-SELF-CROSSLINKED HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
DOP2002000545A (en) SMALL MOLECULES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
MA28909B1 (en) QUINAZOLINES USEFUL AS MODULATORS OF IONIC CHANNELS
SG165315A1 (en) Alpha2c adrenoreceptor agonists
PE20110431A1 (en) DABIGATRAN ETEXYLATE OR A SALT OF THE SAME
DK1654253T3 (en) Substituted 3-pyrrolidine indole derivatives
DE602005023877D1 (en) PROCESS FOR THE PREPARATION OF 7-ALPHA-ALKYLATED 19-NORSTEROIDS
CL2010001123A1 (en) Use of pyridin-3-ylmethyl docosahexanoate to prepare a useful medicine for the prevention and / or treatment of cardiovascular diseases (divisional application 1848-07).
PA8579801A1 (en) PHARMACEUTICAL COMPOSITIONS OF SEMIORDENED AND POLYMER DRUGS
NI200700292A (en) NOVEDOUS AMIDAS DERIVED FROM CARBOXYL PIPERIDIN ACIDS
BRPI0513317A (en) cyclosporins to treat alzheimer's disease
ES2174921T3 (en) HIV PROTEASE INHIBITORS.
ATE381533T1 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR USE
DE60101213D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A SQUALEN EPOXIDASE INHIBITOR AND A MACROLID IMMUNOMODULATOR
CL2007000380A1 (en) Compounds derived from substituted pyrrolo [3,4-c] pyrrole; ccr5 receptor antagonist of ccr5 chemokine, pharmaceutical composition; and its use in the treatment or prevention of infections by human immunodeficiency virus (hiv-1) or to treat AIDS or arc.
PA8577701A1 (en) PEGILATED T20 POLYPEPTIDE
PE20040623A1 (en) COMBINATION OF NMDA ANTAGONIST WITH ACETYLCHOLINE ESTERASE INHIBITORS
AR029155A1 (en) COMBINATION AND USE OF THE SAME IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT TO TREAT CARDIOVASCULAR AFFECTIONS
PE20011049A1 (en) COMBINATION OF DRUGS FOR THE TREATMENT OF DEPRESSION AND RELATED DISORDERS INVOLVING MIRTAZAPINE

Legal Events

Date Code Title Description
FC Refusal